Jori Zemel Foundation
Board of Directors
Event Calendar
Photo Gallery
Press Releases
About Jori Starr Zemel
Poetry & Artwork
Jori's Scrapbook
Photo Gallery
Make A Difference
Donate Online
Spread the Word
Get Involved
Sponsorship Opportunities
Volunteer
Your JZ Headquarters
Create a Webpage
Start a Team
Send Email
Headquarters Log In
  

We Are Proud to Introduce - Dr. Pingyu Zhang
2nd Jori Zemel Scholar and Fellowship Recipient

 

  It is a great honor to me to be selected as a Jori Zemel Scholar and Fellowship recipient. The Jori Zemel Children's Bone Cancer Foundation has provided critical funding to our most talented and motivated osteosarcoma researchers, helping us to make novel discoveries in the laboratory and new therapies to fight osteosarcoma for our young patients. I am inspired by Jori's fight against her osteosarcoma and by Jori's family's strength and passion to help researchers to continue the fight, and to find a cure for ostesarcoma.

I obtained my Bachelor of Science degree in Biology from Nankai University of China in 1994. Then I continued my Master's degree in Molecular Biology and Genetics at the same university. My first research topic is the molecular

mechanisms involved in the gene transcription regulation. My work generated two first author publications, one research paper and one review in Chinese scientific journals. During my PhD study, I studied an important gene regulation mechanism that controls the flower development.

After my PhD study, I came to the world famous institution, The University of Texas M.D. Anderson Cancer Center in 2003. My first project was the function of nuclear localized EGFR (epidermal growth factor receptor) in breast cancer. Although EGFR is a cell membrane binding protein, we found that it can be translocated into nucleus, and we identified a NLS (nuclear localization signal) in the EGFR molecule. We further proved that the mutation in NLS domain can significantly reduce the breast cancer cell proliferation and metastasis in vivo. With the experience on cell signaling and cancer biology, I joined Dr. Hughes' lab and started working on pediatric osteosarcoma in 2005. During the last two years, we have found out an important cell signaling pathway involved in the osteosarcoma cell invasiveness and metastasis. We are able to demonstrate that molecular and genetic inhibition of this signaling pathway can dramatically suppress the pulmonary metastasis of osteosarcoma. More importantly, there are small molecular inhibitors of this signaling pathway available which are being evaluated in clinical trials of several adult cancers, such as T cell leukemia and breast cancer. We hope that these clinical studies, together with our work in the Hughes lab, will enable the rapid development of clinical trials for children with bone cancer. Our findings also suggest that this signaling pathway may serve as a prognostic marker to predict the possibility of the spread of osteosarcoma to the lungs. This will help doctors detect and treat patients early to prevent lung metastasis.

I greatly appreciate the support from the Jori Zemel Children's Bone Cancer Foundation for my research. With this critical support we, scientists and physicians, will fight this disease until every child will survive.
 

For more information on cancer see:                                 

www.childrensoncologygroup.org
www.cancerhelp.org.uk

 
 

Our Mission

It is our goal to save children's lives and end children's bone cancer.  Until that time, the Jori Zemel Children's Bone Cancer Foundation passionately dedicates itself to accomplish the following: educate, fund research and provide financial and emotional support to the children and families affected by this disease.

It was Jori's hope and dream that a day would come when no child's life would ever be compromised
by this disease again.  The Foundation is a tribute to Jori Starr Zemel.

 

Copyright © 2006 - The Jori Zemel Children's Bone Cancer Foundation
A 501(c)3 Non Profit Organization - Tax ID Number 30-0194071